Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-12-09

FDA Approved: SUMATRIPTAN — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application for Sumatriptan submitted by Prasco Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sumatriptan (Sumatriptan)

Snippet

SUPPL AP for SUMATRIPTAN (SUMATRIPTAN)